Drug interactions involving therapeutic radiopharmaceuticals: a systematic review [0.03%]
涉及治疗性放射药物的药物相互作用的系统评价
Robin Gacon,Romane Chapuis,Luca Fabris-Davet et al.
Robin Gacon et al.
Background: Drug interactions with diagnostic radiopharmaceuticals are well recognized, as they can modify biodistribution and lead to false or misleading diagnostic results. However, little is known about such interactio...
Solving the limited availability of Astatine-211 from a European perspective: from production to the end user [0.03%]
从欧洲视角解决砹-211有限可得性问题：从生产到最终用户的问题探究
Sture Lindegren,Holger Jensen,Hans Van de Maele et al.
Sture Lindegren et al.
Background: Astatine-211, 211At, has long been a candidate for Targeted Alpha Therapy, TAT. However, over time, hurdles in the development of chemistry, the establishment of radiopharmacies, and the demonstration of its p...
Increasing the activity output and optimization of automated radiosynthesis [68Ga]Ga-DOTATATE, [68Ga]Ga-Pentixafor, and [68Ga]Ga-FAPI-64 using two [68Ge]Ge/[68Ga]Ga iThemba generators in series [0.03%]
通过串联两个[68Ge]Ge/[68Ga]Ga iThemba 发生器增加自动化放射合成[68Ga]Ga-DOTATATE、[68Ga]Ga-Pentixafor 和 [68Ga]Ga-FAPI-64 的产量及优化
Ammar Alfteimi,Ulf Lützen,Alexander Helm et al.
Ammar Alfteimi et al.
Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging [0.03%]
用于PET成像的两种代谢稳定的GRPR靶向肽的放射性镓-68标记及其治疗潜力研究
Karim Obeid,Ekaterina Bezverkhniaia,Vladimir Tolmachev et al.
Karim Obeid et al.
Background: Gastrin-releasing peptide receptor (GRPR) attracts increasing attention as a target for radiotheranostic applications. We previously developed a metabolically stable GRPR-targeting peptide, incorporating α-me...
A novel 18F-labelled tetrazine ester prosthetic group for improved radiolabelling and in vivo stability of proteins and peptides [0.03%]
一种新型的18F标记四嗪酯模拟物以提高蛋白质和肽的放射性标记以及在体内的稳定性
Francesco Lechi,Luke R Odell,Olivia Wegrzyniak et al.
Francesco Lechi et al.
Background: Monoclonal antibodies, engineered protein scaffolds, and peptides are increasingly important in therapy and diagnostics owing to their high specificity and affinity. Recent advances have enabled radiolabelling...
Balancing innovation and accessibility in infection imaging: lessons from the [99mTc]Tc-besilesomab paradox [0.03%]
感染成像中创新和可及性的平衡：来自[99mTc]Tc-Besilesomab悖论的启示
Océane Mesnilgrante,Typhanie Ladrière,Noémie Allouche et al.
Océane Mesnilgrante et al.
Background: Infection imaging plays a crucial role in clinical decision making, guiding antibiotic therapy and surgical management. Nuclear medicine offers molecular level approaches using three main techniques: [18F]FDG ...
A new 68Ga-labeled dimeric FAP ligand to advance targeted PET imaging of cancer [0.03%]
一种新的68Ga标记的二聚FAP配体，可促进癌症靶向PET影像学的发展
Feng Li,Chaitanya Kondam,Zhen Yang et al.
Feng Li et al.
Background: Fibroblast activation protein (FAP) has emerged as a critical biomarker in the tumor microenvironment of various cancers. Radioligands targeting FAP have shown promise for cancer theranostics. To advance cance...
Synthesis and preclinical development of a novel 68Ga/89Zr-Labelled ανβ6-integrin targeting trimer [0.03%]
新型放射性核素标记的αvβ6整合素靶向三聚体的合成与临床前开发研究
Clemens Decristoforo,Giacomo Gariglio,Fernando A Patiño Álvarez et al.
Clemens Decristoforo et al.
Background: The αvβ6 integrin has emerged as a valuable target for theranostic applications in nuclear medicine with high applicability across a variety of cancers, including head-and-neck, lung, breast, and pancreatic ...
A comparative assessment of radiochemical purity and yield of [18F]PSMA-1007 production using two different automated synthesis platforms: a head-to-head comparison [0.03%]
两种不同自动化合成平台生产[18F]PSMA-1007的放射化学纯度和产率的比较评估：直接对比研究
Michela Cossandi,Massimo Statuto,Elena Migliorati et al.
Michela Cossandi et al.
Background: Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) is overexpressed in 90-100% of prostate cancer cells. The radiopharmaceutical [18F]PSMA-1007, recognised as a PET ...
Quality control of actinium-225 and 225Ac-radiopharmaceuticals: Francium-221 to be or not to be? [0.03%]
靶向锕-225放射性药物的质量控制：镭-221的存在与否？
Miguel Toro-Gonzalez,Luke Wheeless,Vijai Kumar Reddy Tangadanchu et al.
Miguel Toro-Gonzalez et al.
Background: Actinium-225 radiopharmaceuticals have drawn great interest in cancer therapy due to their tumor-specific delivery of cytotoxic alpha-particles. Quality control (QC) is critical for these potent agents and the...